Clinical Trial: Study of IMX-110 in Combination With Tislelizumab in Patients With Advanced Solid Tumors
Study Status: Completed
Recruit Status: RECRUITING
Condition: Advanced Solid Tumor
Study Type: INTERVENTIONAL
Official Title: A Phase 1/2a Open-Label, Dose-Escalation/Dose-Expansion Safety, Tolerability and Anti-tumor Activity Study of IMX-110 in Combination With Tislelizumab in Patients With Advanced Solid Tumors
Brief Summary:
Phase 1/2a Phase 1 is an open-label, multicenter dose escalation/dose expansion study designed to assess the safety, tolerability, pharmacokinetics (PK) and antitumor activity of IMX-110 in combination with Tislelizumab.The recommended Phase 2 dose (RP2D) will be evaluated in further dose expansion Phase 2a study submitted as an amendment to this Phase 1 protocol during the conduct of the Phase 1 study.
Read more